Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials.
Joseph Alexander PaguioBruce Adrian CasipitTara A JohnAniruddh BaluKevin Bryan U LoPublished in: Expert review of cardiovascular therapy (2023)
Among hospitalized patients with COVID-19, the use of ACEi/ARB was not associated with increased risk of mortality, ICU admission, or mechanical ventilation compared to control. These findings support continuation of ACEi/ARB for whom baseline clinical indications for these agents exist.
Keyphrases
- angiotensin converting enzyme
- mechanical ventilation
- angiotensin ii
- intensive care unit
- acute respiratory distress syndrome
- vascular smooth muscle cells
- respiratory failure
- emergency department
- cardiovascular events
- extracorporeal membrane oxygenation
- risk factors
- clinical trial
- type diabetes
- cardiovascular disease
- binding protein
- skeletal muscle
- weight loss